BCIQ Profiles

Company Profile Report

Efficacy data set trastuzumab ADC up for fast approval for third-line breast cancer

Less than two weeks after establishing a new threshold for efficacy in HER2+ breast cancer, Enhertu fam-trastuzumab deruxtecan-nxki has gained accelerated approval from FDA in the indication

Read the full 276 word article

How to gain access

Continue reading with a
two-week free trial.